Small molecule · Inhibitor of calcium release-activated calcium channel protein 1 (Orai1) (ORAI1) · developed by CalciMedica
Zegocractin (CM4620) is an inhibitor of the calcium release-activated calcium (CRAC) channel that binds Orai1, the pore-forming protein of the channel, blocking extracellular calcium entry into cells. It reduces calcium-mediated signaling and the release of inflammatory cytokines such as IL-2 and TNF-alpha. It has been studied in acute pancreatitis, systemic inflammatory response syndrome, and pneumonia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04681066 | Phase 2 | Acute Pancreatitis | Completed | CALC |
| NCT04661540 | Phase 2 | Pneumonia | Terminated | CALC |
| NCT04195347 | Phase 1/2 | Acute Pancreatitis | Recruiting | CALC |
| NCT03709342 | Phase 2 | Acute Pancreatitis | Completed | CALC |
| NCT03401190 | Phase 2 | Acute Pancreatitis | Completed | CALC |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute PancreatitisPneumoniaSystemic Inflammatory Response Syndrome
Updated Nov 8, 2026. Something wrong or missing? Report it on the CALC page.
See CALC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CALC catalysts and pipeline →